Goldman Sachs
CPIX icon

Goldman Sachs’s Cumberland Pharmaceuticals CPIX Stock Holding History

Goldman Sachs’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-59,071
Closed -$268K – 6662
2013
Q3 		$268K Sell
59,071
-2,818
-5% -$14K ﹤0.01% 5648
2013
Q2 		$316K Buy
+61,889
New +$308K ﹤0.01% 5294

Other funds holding CPIX

AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KIM
Kestrel Investment Management San Mateo, California $167M AUM 20.81% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GHA
GW Henssler & Associates Kennesaw, Georgia $2.12B AUM 20.77% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

Goldman Sachs's CPIX Position: Q4 2013 in Review

Goldman Sachs sold out of Cumberland Pharmaceuticals (CPIX) in Q4 2013, closing a stake of 59,071 shares — an estimated $268K sold.

Goldman Sachs first reported a position in CPIX in Q2 2013 and held it in 2 quarters. The position peaked at $316K in Q2 2013. 45 funds tracked by Wall St. Rank hold CPIX as of Q4 2013.

  • Goldman Sachs reported no remaining Cumberland Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Goldman Sachs sold 59,071 Cumberland Pharmaceuticals shares in Q4 2013, an estimated $268K.
  • Goldman Sachs first reported a position in Cumberland Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Goldman Sachs's Cumberland Pharmaceuticals position peaked at $316K in Q2 2013.
  • 45 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q4 2013.

Based on Goldman Sachs's 13F filing for Q4 2013, filed 14 Feb 2014.